Aptatek Initial Close Funds PheCheck Clinical Program

Aptatek Biosciences has announced the initial close of an undisclosed financing round led by Canterbury Scientific Ltd. and Longview Innovation. The Princeton, New Jersey clinical-stage diagnostics company will use the money to support the clinical evaluation and continued development of PheCheck, its investigational system for quantitative phenylalanine monitoring at home.

PheCheck is the first application of Aptatek's connected HomeCheck platform. The system combines DNA aptamer sensing, a reusable handheld reader, a single-use cartridge, and a smartphone-connected application. Aptatek is developing it for people living with phenylketonuria, or PKU, who may need lifelong monitoring of blood phenylalanine levels to guide diet, medication, and clinical care.

The financing arrives at the point where Aptatek's core argument has to move from product design into clinical evidence. PheCheck has received FDA Breakthrough Device designation, but it remains investigational, has not been cleared or approved by the FDA, and is not commercially available. Aptatek expects its ongoing clinical study to finish before the end of 2026 and plans to use the data in a future regulatory submission.

What Aptatek Announced

The September 29, 2026 financing announcement describes an initial close led by Canterbury Scientific and Longview Innovation. Aptatek did not disclose the amount, valuation, security type, final-close target, or complete syndicate, so the transaction cannot be safely labeled as a Seed, Series A, or final close.

The proceeds are directed toward the clinical evaluation and continued development of PheCheck. Aptatek says it has already completed preclinical analytical work that included comparison with LC-MS reference testing. Its registered validation study, NCT07551921, is evaluating rapid quantitative phenylalanine measurement from fingerstick blood samples in people with PKU or hyperphenylalaninemia.

That distinction matters. The financing supports the evidence-generation phase. It does not establish clinical performance, regulatory clearance, commercial availability, reimbursement, or adoption.

Why PheCheck Matters for PKU Monitoring

PKU is an inherited metabolic disorder in which phenylalanine can accumulate to harmful levels. NICHD guidance explains that treatment can require lifelong dietary management, frequent blood testing, and regular clinical follow-up. Blood samples may be collected at home and mailed to a laboratory, which separates sample collection from the result used by a patient and care team.

Aptatek is trying to change that information flow. PheCheck is designed to pair a fingerstick sample with a single-use cartridge, portable reader, and connected application. The company says the system can preserve measurements over time and share them with authorized care teams, potentially bringing quantitative information closer to the decisions it supports.

The patient value depends on more than speed. A home result has to be analytically reliable, clinically useful, secure, understandable, and integrated into professional care. That is why clinical evaluation and regulatory review are the center of this financing story rather than a procedural footnote.

The Science Behind Aptatek

Aptatek is a Columbia University spinout built on DNA aptamer technology developed in the laboratories of co-founders Tilla Worgall, MD, PhD, and Milan Stojanovic, PhD. Aptamers are engineered nucleic-acid sequences designed to bind selected molecular targets. Aptatek is applying that approach to small-molecule biomarkers that can be difficult to measure with antibody-based tests outside a central laboratory.

Michael Boyce-Jacino, PhD, leads Aptatek as CEO and president. The broader HomeCheck strategy is to extend the connected sensing platform into additional metabolic biomarkers, therapeutic drug monitoring, and companion-diagnostic applications. Those areas remain development ambitions. PheCheck and the current PKU clinical program are the verified near-term focus.

The company is also working with Lumos Diagnostics, which announced a $1.5M development-services contract in 2025 covering device maturation, formal verification, validation, and clinical-study support. That contract value is a payment to a development partner, not an Aptatek financing amount.

Why the Investors Fit the Work

Canterbury Scientific is a repeat Aptatek investor and a specialist in in vitro diagnostic controls and calibrators. Longview Innovation invests in science-based companies built from university and national-laboratory intellectual property, and it lists Aptatek in its portfolio. Their participation connects financing to the practical work of moving academic sensing technology through device development, clinical validation, manufacturing preparation, and commercialization planning.

Aptatek previously completed a $4M Seed round in 2022 led by IP Group, with Canterbury Scientific and the National PKU Alliance participating. The company later announced an additional undisclosed funding tranche in 2024 and undisclosed bridge financing from Canterbury Scientific in 2025. Because those later amounts were not published, a precise total funding figure cannot be verified.

What the Initial Close Signals

This financing puts capital behind the least theatrical and most consequential part of decentralized diagnostics: proving that a measurement made closer to the patient can retain the quality needed for clinical use. The current system makes many people with PKU move blood samples through a logistics chain before information returns. Aptatek is attempting to move the measurement without weakening the evidence.

The next milestones will come from the clinical study, the planned regulatory submission, and the product's ability to work inside PKU care rather than beside it. If PheCheck succeeds, the result will be more than a portable test. It will be a different handoff between patient, measurement, and care team. The initial close gives Aptatek more room to demonstrate that the handoff deserves trust.